Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4399-4413

  Mascarenhas, J ^a   Mughal, T I ^b   Verstovsek, S ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Essential thrombocythemia; JAK inhibitor; JAK STAT; Janus kinase; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera; Primary myelofibrosis; Quality of life; Ruxolitinib; Splenomegaly; Symptoms

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ACETYLSALICYLIC ACID; ANAGRELIDE; ANTIANEMIC AGENT; BCR ABL PROTEIN; BORTEZOMIB; BUSULFAN; CORTICOSTEROID; ERLOTINIB; EVEROLIMUS; GANDOTINIB; GIVINOSTAT; HYDROXYUREA; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MELPHALAN; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PANOBINOSTAT; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RUXOLITINIB; THALIDOMIDE; UNINDEXED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTERY THROMBOSIS; BLOOD VISCOSITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CYTOREDUCTIVE SURGERY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EPIGENETICS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMATOCRIT; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHLEBOTOMY; PLASMA VOLUME; POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS;

HUMANS; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRAZOLES; SIGNAL TRANSDUCTION;

EID: 84868015186     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251511     Document Type: Review

References (107)

1. Tefferi, A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 2010, 24(6), 1128-1138.
2. Tefferi, A.; Vardiman, J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008, 22(1), 14-22.
3. Tefferi, A.; Thiele, J.; Orazi, A.; Kvasnicka, H.M.; Barbui, T.; Hanson, C.A.; Barosi, G.; Verstovsek, S.; Birgegard, G.; Mesa, R.; Reilly, J.T.; Gisslinger, H.; Vannucchi, A.M.; Cervantes, F.; Finazzi, G.; Hoffman, R.; Gilliland, D.G.; Bloomfield, C.D.; Vardiman, J.W. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110(4), 1092-1097.
4. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; Scott, M.A.; Erber, W.N.; Green, A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464), 1054-1061.
5. James, C.; Ugo, V.; Le Couedic, J.P., Staerk, J.; Delhommeau, F.; Lacout, C.; Garçon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J.L.; Constantinescu, S.N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434(7037), 1144-1148.
6. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 2005, 352(17), 1779-1790.
7. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J.C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Fröhling, S.; Döhner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R.A.; Tefferi, A.; Griffin, J.D.; Eck, M.J.; Sellers, W.R.; Meyerson, M.; Golub, T.R.; Lee, S.J.; Gilliland, D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7(4), 387-397.
8. Zhao, R.; Xing, S.; Li, Z.; Fu, X.; Li, Q.; Krantz, S.B.; Zhao, Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem., 2005, 280(24), 22788-22792.
9. Tefferi, A.; Skoda, R; Vardiman, J.W. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat. Rev. Clin. Oncol., 2009, 6(11), 627-637.
10. Verstovsek, S. Therapeutic potential of JAK2 inhibitors. Hematology Am. Soc. Hematol. Educ. Program, 2010, 16(7), 1988-1996.
11. Passamonti, F.; Maffioli, M.; Caramazza, D.; Cazzola, M. Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2011, 2(6), 485-490.
12. Walter, M.J.; Ding, L.; Shen, D.; Shao, J.; Grillot, M.; McLellan, M.; Fulton, R.; Schmidt, H.; Kalicki-Veizer, J.; O'Laughlin, M.; Kandoth, C.; Baty, J.; Westervelt, P.; DiPersio, J.F.; Mardis, E.R.; Wilson, R.K.; Ley, T.J.; Graubert, T.A. Recurrent DNMT3A mutations in patients with myelodys-plastic syndromes. Leukemia, 2011, 25(7), 1153-1158.
13. Berlin, N.I. Diagnosis and classification of the polycythemias. Semin. Hematol., 1975, 12(4), 339-351.
14. Michiels J.J.; De Raeve, H.; Berneman, Z. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin. Thromb. Hemost., 2006, 32(4, Pt. 2), 307-340.
15. Passamonti, F.; Rumi, E.; Caramella, M.; Elena, C.; Arcaini, L.; Boveri, E.; Del Curto, C.; Pietra, D.; Vanelli, L.; Bernasconi, P.; Pascutto, C.; Cazzola, M.; Morra, E.; Lazzarino, M. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood, 2008, 111(7), 3383-3387.
16. Passamonti, F.; Cervantes, F.; Vannucchi, A.M.; Morra, E.; Rumi, E.; Pereira, A.; Guglielmelli, P.; Pungolino, E.; Caramella, M.; Maffioli, M.; Pascutto, C.; Lazzarino, M.; Cazzola, M.; Tefferi, A. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115(9), 1703-1708.
17. Budde, U.; Scharf, R.E.; Franke, P.; Hartmann-Budde, K.; Dent, J.; Ruggeri, Z.M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 1993, 82(6), 1749-1757.
18. Finazzi, G.; Barbui, T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev., 2005, 19(5), 243-252.
19. Barbui, T.; Barosi, G.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Griesshammer, M.; Harrison, C.; Hasselbalch, H.C.; Hehlmann, R.; Hoffman R.; Kiladjian, J.J.; Kröger, N.; Mesa, R.; McMullin, M.F.; Pardanani, A.; Passamonti, F.; Vannucchi, A.M.; Reiter, A.; Silver, R.T.; Verstovsek, S.; Tefferi, A.; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol., 2011, 29(6), 761-770.
20. Tefferi, A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 2011, 86(3), 292-301.
21. Barosi, G.; Birgegard, G.; Finazzi, G.; Griesshammer, M.; Harrison, C.; Hasselbalch, H.C.; Kiladjian, J.J.; Lengfelder, E.; McMullin, M.F.; Passamonti, F.; Reilly, J T.; Vannucchi, A.M.; Barbui, T. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113(20), 4829-4833.
22. Pearson, T.C.; Weatherly-Mein, G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 1978, 2(8102), 1219-1221.
23. Finazzi, G.; Barbui, T. How I treat patients with polycythemia vera. Blood, 2007, 109(12), 5104-5111.
24. Menagé, H.D.; Norris, P.G.; Hawk, J.L.; Graves, M.W. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. B r. J. Dermatol., 1993, 129(2), 163-165.
25. Finelli, C.; Gugliotta, L.; Gamberi, B.; Vianelli, N.; Visani, G.; Tura, S. Relief of intractable pruritus in polycythemia vera with recombinant inter-feron alfa. Am. J. Hematol., 1993, 43(4), 316-318.
26. Squizzato, A.; Romualdi, E.; Middeldorp, S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst. Rev., 2008, (2), CD006503.
27. Landolfi, R.; Marchioli, R.; Kutti, J.; Gisslinger, H.; Tognoni, G.; Patrono, P.; Barbui, T.; the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med., 2010, 350(2), 114-124.
28. Finazzi, G.; Caruso, V.; Marchioli, R.; Capnist, G.; Chisesi, T.; Finelli, C.; Gugliotta, L.; Landolfi, R.; Kutti, J.; Gisslinger, H.; Marilus, R.; Patrono, C.; Pogliani, E.M.; Randi, M.L.; Villegas, A.; Tognoni, G.; Barbui, T. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 2005, 105(7), 2664-2670.
29. Najean, Y.; Rain, J.D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 1997, 90(9), 3370-3377.
30. Kiladjian, J.J.; Rain, J.D.; Bernard, J.F.; Briere, J., Chomienne, C., Fenaux, P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost., 2006, 32(4, Pt. 2), 417-421.
31. Kiladjian, J.J.; Chevret, S.; Dosquet, C.; Chomienne, C.; Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J. Clin. Oncol., 2011, 29(29), 3907-3913.
32. Hasselbalch, H.C.; Kiladjian, J.J.; Silver, R.T. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J. Clin. Oncol., 2011, 29(18), e564-e565.
33. Kiladjian, J.J.; Cassinat, B.; Chevret, S.; Turlure, P.; Cambier, N.; Roussel, M.; Bellucci, S.; Grandchamp, B.; Chomienne, C.; Fenaux, P. Pegylated in-terferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008, 112(8), 3065-3072.
34. Fabris, F.; Randi, M.L. Essential thrombocythemia: past and present. Intern. Emerg. Med., 2009, 4(5), 381-388.
35. Mesa, R.A.; Niblack, J.; Wadleigh, M.; Verstovsek, S.; Camoriano, J.; Barnes, S.; Tan, A.D.; Atherton, P.J.; Sloan, J.A.; Tefferi, A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer, 2007, 109(1), 68-76.
36. Jensen, M.K.; de Nully Brown, P.; Lund, B.V.; Nielsen, O.J.; Hasselbalch, H.C. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur. J. Haematol., 2001, 66(3), 143-151.
37. Arellano-Rodrigo, E.; Alvarez-Larran, A.; Reverter, J.C.; Villamor, N.; Colomer, D.; Cervantes, F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 2006, 91(2), 169-175.
38. Cortelazzo, S.; Finazzi, G.; Ruggeri, M.; Vestri, O.; Galli, M.; Rodeghiero, F.; Barbui, T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med., 1995, 332(17), 1132-1136.
39. Spivak, J.L.; Barosi, G.; Tognoni, G.; Barbui, T.; Finazzi, G.; Marchioli, R.; Marchetti, M. Chronic myeloproliferative disorders. Hematol. Am. Soc. Hematol. Educ. Prog., 2003, 200-224.
40. Quintás-Cardama, A.; Kantarjian, H.; Manshouri, T.; Luthra, R.; Estrov, Z.; Pierce, S.; Richie, M.A.; Borthakur, G.; Konopleva, M.; Cortes, J.; Verstovsek, S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol., 2009, 27(32), 5418-5424.
41. Harrison, C.N.; Campbell, P.J.; Buck, G.; Wheatley, K.; East, C.L.; Bareford, D.; Wilkins, B.S.; van der Walt, J.D.; Reilly, J.T.; Grigg, A.P.; Revell, P.; Woodcock, B.E.; Green, A.R. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med., 2005, 353(1), 33-45.
42. van Genderen, P.J.; Mulder, P.G.; Waleboer, M.; van de Moesdijk, D.; Michiels, J.J. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br. J. Haematol., 1997, 97(1), 179-184.
43. Zhan, H.; Spivak, J.L. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin. Adv. Hematol. Oncol., 2009, 7(5), 334-342.
44. Cervantes, F.; Dupriez, B.; Pereira, A.; Passamonti, F.; Reilly, J.T.; Morra, E.; Vannucchi, A.M.; Mesa, R.A.; Demory, J.L.; Barosi, G.; Rumi, E.; Tefferi, A. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113(13), 2895-2901.
45. Tefferi, A. Management of myeloproliferative neoplasms and the promise of targeted therapy. American Society of Clinical Oncology (ASCO) Educational Book, 2008, 346-348.
46. Gangat, N.; Caramazza, D.; Vaidya, R.; George, G.; Begna, K.; Schwager, S.; Hanson, C.; Wu, W.; Pardanani, A.; Cervantes, F.; Passamonti, F.; Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol., 2011, 29(4), 392-397.
47. Tefferi, A. How I treat myelofibrosis. Blood, 2011, 117(13), 3494-3504.
48. Tefferi, A. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant., 2010, 45(3), 419-421.
49. Ballen, K.K.; Shrestha, S.; Sobocinski, K.A.; Zhang, M.J.; Bashey, A.; Bolwell, B.J.; Cervantes, F.; Devine, S.M.; Gale, R.P.; Gupta, V.; Hahn, T.E.; Hogan, W.J.; Kröger, N.; Litzow, M.R.; Marks, D.I.; Maziarz, R.T.; McCarthy, P.L.; Schiller, G.; Schouten, H.C.; Roy, V.; Wiernik, P.H.; Horowitz, M.M.; Giralt, S.A.; Arora, M. Outcome of transplantation for myelofibrosis. Biol. Blood Marrow Transplant, 2010,16(3), 358-367.
50. Patriarca, F.; Bacigalupo, A.; Sperotto, A.; Isola, M.; Soldano, F.; Bruno, B.; van Lint, M.T.; Iori, A.P.; Santarone, S.; Porretto, F.; Pioltelli, P.; Visani, G.; Iacopino, P.; Fanin, R; Bosi, A.; GITMO. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 2008, 93(10), 1514-1522.
51. Rondelli, D.; Goldberg, J.D.; Marchioli, R; Isola, L.; Shore, T.B.; Prchal, J.T.; Bacigalupo, A.; Rambaldi, A.; Klisovic, R.B.; Gupta, V.; Andreasson, B.; Demakos, E.P.; Price, L.S.; Scarano, M.; Wetzler, M.; Vannucchi, A.M.; Najfeld, V.; Barosi, G.; Silverman, L.R; Hoffman, R Results of phase II clinical trial MPD-RC 101: allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis. Blood [ASH Annual Meeting Abstracts], 2011, 118(21), [Abstract 1750].
52. Arana-Yi, C; Quintás-Cardama, A.; Giles, F.; Thomas, D.; Carrasco-Yalan, A.; Cortes, J.; Kantarjian, H.; Verstovsek, S. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist, 2006, 11(8), 929-943.
53. Silver, R.T.; Vandris, K.; Goldman, J. Recombinant interferon-α may retard the progression of early primary myelofibrosis: a preliminary report. Blood, 2011,117(24), 6669-6672.
54. Vainchenker, W.; Dusa, A.; Constantinescu, S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin. Cell Dev. Biol, 2008, 19(4), 385-393.
55. Wilks, A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A., 1989, 86(5), 1603-1607.
56. Wilks, A.F.; Harpur, A.G.; Kurban, RR; Ralph, S.J.; Zurcher, G.; Ziemiecki, A. Two novel protein-tyrosine kinases, each with a second phosphotransferase related catalytic domain, define a new class of protein kinase. Mol. Cell Biol, 1991, 11(4), 2057-2065.
57. Watowich, S.S.; Wu, H.; Socolovsky, M.; Klingmuller, U.; Constantinescu, S.N.; Lodish, H.F. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu. Rev. Cell Dev. Biol, 1996, 12, 91-128.
58. Firmbach-Kraft, I.; Byers, M.; Shows, T.; Dalla-Favera, R; Krolewski, J.J. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene, 1990,5(9), 1329-1336.
59. Riedy, M.C.; Dutra, A.S.; Blake, T.B.; Modi, W.; Lal, B.K.; Davis, J.; Bosse, A.; O'Shea, J.J.; Johnston, J.A. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics, 1996, 37(1), 57-61.
60. Leonard, W.J.; O'Shea, J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol, 1998,16, 293-322.
61. Radtke, S.; Haan, S.; Jörissen, A.; Hermanns, H.M.; Diefenbach, S.; Smyczek, T.; Schmitz-Vandeleur, H.; Heinrich, P.C.; Behrmann, I.; Haan C. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J. Biol. Chem., 2005, 280(27), 25760-25768.
62. Ghoreschi, K.; Laurence, A.; O'Shea, J.J. Janus kinases in immune cell signaling. Immunol Rev, 2009, 228(1), 273-287.
63. Sandberg, E.M.; Wallace, T.A.; Godeny, M.D.; Von Der Linden, D.; Sayeski, P.P. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem. Biophys., 2004, 41(2), 207-232.
64. Lohi, O.; Lehto, V.P. STAM/EAST/Hbp adapter proteins - integrators of signalling pathways. FEBS Lett, 2001, 508(3), 287-290.
65. Rawlings, J.S.; Rosler, K.M.; Harrison, D.A. The JAK/STAT signaling pathway. J. Cell Sci, 2004, 117(Pt. 8), 1281-1283.
66. O'Brien, K.B.; O'Shea, J.J.; Carter-Su, C. SH2-B family members differentially regulate JAK family tyrosine kinases. J. Biol. Chem., 2002, 277(10), 8673-8681.
67. Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol, 2007, 7(6), 454-465.
68. Johnston, J.A.; O'Shea, J.J. Matching SOCS with function. Nat. Immunol, 2003, 4(6), 507-509.
69. Oppliger Leibundgut, E.; Horn, M.P., Brunold, C; Pfanner-Meyer, B.; Marti, D.; Hirsiger, H.; Tobler, A.; Zwicky, C. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica, 2006, 91(11), 1465-1472.
70. Tiedt, R; Hao-Shen, H.; Sobas, M.A.; Looser, R.; Dirnhofer, S.; Schwaller, J.; Skoda, RC. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood, 2008, 111(8), 3931-3940.
71. Delhommeau, F.; Jeziorowska, D.; Marzac, C; Casadevall, N. Molecular aspects of myeloproliferative neoplasms. Int. J. Hematol, 2010, 91(2), 165-173.
72. Dawson, M.A.; Bannister, A.J.; Göttgens, B.; Foster, S.D.; Bartke, T.; Green, A.R; Kouzarides, T. JAK2 phosphorylates histone H3Y41 and excludes HPI alpha from chromatin. Nature, 2009, 461(7265), 819-822.
73. Butcher, CM.; Hahn, U.; To, L.B.; Gecz, J.; Wilkins, E.J.; Scott, H.S.; Bardy, P.G.; DAndrea, RJ. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia, 2008, 22(4), 870-873.
74. Abdel-Wahab, O.; Pardanani, A.; Bernard, O.A.; Finazzi, G.; Crispino, J.D.; Gisslinger, H.; Kralovics, R.; Odenike, O.; Bhalla, K.; Guptas, V.; Barosi, G.; Gotlib, J.; Guglielmelli, P.; Kiladjian, J.-J.; Noel, P.; Cazzola, M.; Vannucchi, A.M.; Hoffman, R.; Barbui, T.; Thiele, J.; Van Etten, R.A.; Mughal, T.; Tefferi, A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th International Post-ASH Symposium. Am. J. Hematol. [Online early access], DOI: 10.1002/ajh.23169. Published Online: Mar 28, 2012. http://onlinelibrary.wiley.com/doi/10.1002/ajh. 23169/ abstract [Accessed Apr 3, 2012].
75. Pikman, Y.; Lee, B.H.; Mercher, T.; McDowell, E.; Ebert, B.L.; Gozo, M.; Cuker, A.; Wernig, G.; Moore, S.; Galinsky, I.; DeAngelo, D.J.; Clark, J.J.; Lee, S.J.; Golub, T.R.; Wadleigh, M.; Gilliland, D.G.; Levine, R.L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 2006, 3(7), e270.
76. Abdel-Wahab, O.; Pardanani, A.; Rampal, R.; Lasho, T.L.; Levine, R.L.; Tefferi, A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia, 2011, 25(7), 1219-1220.
77. Stegelmann, F.; Bullinger, L.; Schlenk, R.F.; Paschka, P.; Griesshammer, M.; Blersch, C.; Kuhn, S.; Schauer, S.; Döhner, H.; Döhner, K. DNMT3A mutations in myeloproliferative neoplasms. Leukemia, 2011, 25(7), 1217-1219.
78. Ernst, T.; Chase, A.J.; Score, J.; Hidalgo-Curtis, C.E.; Bryant, C.; Jones, A.V.; Waghorn, K.; Zoi, K.; Ross, F.M.; Reiter, A.; Hochhaus, A.; Drexler, H.G.; Duncombe, A.; Cervantes, F.; Oscier, D.; Boultwood, J.; Grand, F.H.; Cross, N.C.P. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet., 2010, 42(8), 722-726.
79. Brecqueville, M.; Cervera, N.; Adélaïde, J.; Rey, J.; Carbuccia, N.; Chaffanet, M.; Mozziconacci, M.J.; Vey, N.; Birnbaum, D.; Gelsi-Boyer, V.; Mruati, A. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J., 2011, 1, e33.
80. Score, J.; Hidalgo-Curtis, C.; Jones, A.V.; Winkelmann, N.; Skinner, A.; Ward, D.; Zoi, K.; Ernst, T.; Stegelmann, F.; Döhner, K.; Chase, A.; Cross, N.C. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood, 2012, 119(5), 1208-1213.
81. Puda, A.; Milosevic, J.D.; Berg, T.; Klampfl, T.; Harutyunyan, A.S.; Gisslinger, B.; Rumi, E.; Pietra, D.; Malcovati, L.; Elena, C.; Doubek, M.; Steurer, M.; Tosic, N.; Pavlovic, S.; Guglielmelli, P.; Pieri, L.; Vannucchi, A.M.; Gisslinger, H.; Cazzola, M.; Kralovics, R. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am. J. Hematol. [Online early access], DOI: 10.1002/ajh.22257. Published Online: Dec 21, 2011. http://onlinelibrary.wiley.com/doi/10.1002/ajh.22257/abstract [Accessed Apr 3, 2012].
82. Vainchenker, W.; Delhommeau, F.; Constantinescu, S.N.; Bernard, O.N. New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011, 118, 1723-1735.
83. Sanada, M.; Suzuki, T.; Shih, L.Y.; Otsu, M.; Kato, M.; Yamazaki, S.; Tamura, A.; Honda, H.; Sakata-Yanagimoto, M.; Kumano, K.; Oda, H.; Yamagata, T.; Takita, J.; Gotoh, N.; Nakazaki, K.; Kawamata, N.; Onodera, M.; Nobuyoshi, M.; Hayashi, Y.; Harada, H.; Kurokawa, M.; Chiba, S.; Mori, H.; Ozawa, K.; Omine, M.; Hirai, H.; Nakauchi, H.; Koeffler, H.P.; Ogawa, S. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 2009, 460(7257), 904-908.
84. Abdel-Wahab, O.; Manshouri, T.; Patel, J.; Harris, K.; Yao, J.; Hedvat, C.; Heguy, A.; Bueso-Ramos, C.; Kantarjian, H.; Levine, R.L.; Verstovsek, S. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res., 2010, 70(2), 447-452.
85. Couronné, L.; Lippert, E.; Andrieux, J.; Kosmider, O.; Radford-Weiss, I.; Penther, D.; Dastugue, N.; Mugneret, F.; Lafage, M.; Gachard, N.; Nadal, N.; Bernard, O.A.; Nguyen-Khac, F. Analyses of TET2 mutations in postmyeloproliferative neoplasm acute myeloid leukemias. Leukemia, 2010, 24(1), 201-203.
86. Tefferi, A.; Levine, R.L.; Lim, K.H.; Abdel-Wahab, O.; Lasho, T.L.; Patel, J.; Finke, C.M.; Mullally, A.; Li, C.Y.; Pardanani, A.; Gilliland, D.G. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia, 2009, 23(5), 900-904.
87. Bruchova, H.; Merkerova, M.; Prchal, J.T. Aberrant expression of microRNA in polycythemia vera. Haematologica, 2008, 93(7), 1009-1016.
88. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J.; Verstovsek, S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov., 2011, 10(2), 127-140.
89. Quintas-Cardama, A.; Verstovsek, S. Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer [Online early access], DOI: 10.1002/cncr.26359. Published Online: Jul 15, 2011. http://onlinelibrary.wiley. com/doi/10.1002/cncr.26359/abstract;jsessionid=F FD3E21A4D8DF570833EF6ECF4B333FE.d02t03 [Accessed Jan 16, 2012].
90. Pardanani, A.; Gotlib, J.R.; Jamieson, C.; Cortes, J.E.; Talpaz, M., Stone, R.M.; Silverman, M.H.; Gilliang, D.G.; Shorr, J.; Tefferi, T. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol., 2011, 29(7), 789-796.
91. Knapper, S.; Burnett, A.K.; Littlewood, T.; Kell, W.J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M.J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108(10), 3262-3270.
92. Smith, B.D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K.M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004, 103(10), 3669-3676.
93. Pardanani, A.; Lasho, T.; Smith, G.; Burns, C.J.; Fantino, E.; Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from poly-cythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.
94. Tyner, J.W.; Bumm, T.G.; Deininger, J.; Wood, L.; Aichberger, K.J.; Loriaux, M.M.; Druker, B.J.; Burns, C.J.; Fantino, E.; Deininger, M.W. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.
95. Pardanani, A.; George, G.; Lasho, T.; Hogan, W.J.; Litzow, M.R.; Begna, K.; Hanson, C.A.; Fida, R.; Burns, C.; Smith, G.D.; Tefferi, A. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood [ASH Annual Meeting Abstracts], 2010, 116 (21), [Ab str act 46 0].
96. Komrokji, R.S.; Wadleigh, M.; Seymore, J.F.; Roberts, A.W.; Bik To, L.; Zhu, H.J.; Mesa, R.A. Results of a phase 2 study of Pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood [ASH Annual Meeting Abstracts], 2011, 118(21), [Abstract 282].
97. Hedvat, M.; Huszar, D.; Herrmann, A.; Gozgit, J.M.; Schroeder, A.; Sheehy, A.; Buettner, R.; Proia, D.; Kowolik, C.M.; Xin, H.; Armstrong, B.; Bebernitz, G.; Weng, S.; Wang, L.; Ye, M.; McEachern, K.; Chen, H.; Morosini, D.; Bell, K.; Alimzhanov, M.; Ioannidis, S.; McCoon, P.; Cao, Z.A.; Yu, H.; Jove, R.; Zinda, M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell, 2009, 16(6), 487-497
98. Quintás-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P.A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J.D.; Haley, P.; Kantarjian, H.; Fridman, J.S.; Verstovsek, S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.
99. Shilling, A.D.; Nedza, F.M.; Emm, T.; Diamond, S.; McKeever, E.; Punwani, N.; Williams, W.; Arvanitis, A.; Galya, L.G.; Li, M.; Shepard, S.; Rodgers, J.; Yue, T.Y.; Yeleswaram, S. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab. Dispos., 2010, 38(11), 2023-2031.
100. Shi, J.G.; Chen, X.; Emm, T.; Scherle, P.A.; McGee, R.F.; Lo, Y.; Landman, R.R.; McKeever, E.G., Jr.; Punwani, N.G.; Williams, W.V.; Yeleswaram, S. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib in healthy volunteers. J. Clin. Pharmacol., [Online early access] DOI: 10.1177/0091270011405663. Published Online: May 20, 2011. http://jcp.sagepub.com/content/early/2011/05/20/ 0091270011405663 [Accessed Jan 16, 2012].
101. Verstovsek, S.; Kantarjian, H.; Mesa, R.A.; Pardanani, A.D.; Cortes-Franco, J.; Thomas, D.A.; Estrov, Z.; Fridman, J.S.; Bradley, E.C.; Erickson-Viitanen, S.; Vaddi, K.; Levy, R.; Tefferi, A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med., 2010, 363(12), 1117-1127.
102. Mesa, R.A.; Verstovsek, S.; Kantarjian, H.M.; Pardanani, A.D.; Friedman, S.; Newton, R.; Erickson-Viitanen, S.; Hunter, D.; Redman, J.; Yeleswaram, S.; Bradley, E.; Tefferi, A. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF). Blood [ASH Annual Meeting Abstracts], 2008, 112(11), [Abstract 1760].
103. Verstovsek, S.; Mesa, R.A.; Gotlib, J.; Levy, R.S.; Gupta, V.; DiPersio, J.F.; Catalano, J.V.; Deininger, M.; Miller, C.; Silver, R.T.; Talpaz, M.; Winton, E.F.; Harvey, J.H., Jr.; Arcasoy, M.O.; Hexner, E.; Lyons, R.M.; Paquette, R.; Raza, A.; Vaddi, K.; Erickson-Viitanen, S.; Koumenis, I.L.; Sun, W.; Sandor, V.; Kantarjian, H.M. A double-blind placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med., 2012, 366(9), 799-807.
104. Mesa, R.; Gotlib, J.; Gupta, V.; DiPersio, J.; Catalano, J.; Deininger, M.; Sheilds, A.; Miller, C.; Silver, R.; Talpaz, M.; Winton, E.; Harvey, J.; Hare, T.; Erickson-Viitanen, S.; Sun, W.; Sandor, V.; Levy, R.; Kantarjian, H.; Verstovsek, S.; COMFORT-I Investigators. Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF. Blood [ASH Annual Meeting Abstracts], 2011, 118(21), [Abstract 3842].
105. Harrison, C.; Kiladjian, J.J.; Al-Ali, H.K.; Gisslinger, H.; Waltzman, R.; Stalbovskaya, V.; McQuitty, M.; Hunter, D.S.; Levy, R.S.; Knoops, L.; Cervantes, F.; Vannucchi, A.M.; Barbui, T.; Barosi, G. JAK inhibition with ruxolitinib vs best available therapy in myelofibrosis. N. Engl. J. Med., 2012, 366(9), 787-798.
106. Verstovsek, S.; Deeg, H.J.; Odenike, O.; Zhu, J.; Kantarjian, H.; Estrov, Z.; Scott, B.L.; Thomas, D.A. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood [ASH Annual Meeting Abstracts], 2010, 116, [Abstract 3082].
107. Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P.J.; Levy, R.; Bradley, E.; Garrett, W.; Vaddi, K.; Contel, N.; Sandor, V.; Huber, R.M.; Schacter, L.P.; Rumi, E.; Gattoni, E.; Antonioli, E.; Pieri, L.; Cazzola, M.; Kantarjian, H.; Barbui, T.; Vannucchi, A.M. Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood [ASH Annual Meeting Abstracts], 2010, 116(21), [Abstract 313].